Project Grant R21HD113931
Award Date
8/23/24
Completion Date
7/31/26
Dollars Obligated
$253K
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Emigration Canyon, UT 84108, USA
Similar Awards
This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) aims to improve the reach and efficacy of gene therapy by leveraging endogenously produced extracellular vesicles (EVs) to transport engineered transgene mRNA or protein products among cells and across tissues. The $430,375 project, awarded to Emory University, will test the hypothesis that EV-facilitated transfer of transgene-encoded...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under CFDA program 93.865 Child Health and Human Development Extramural Research, is providing $192,056 to the Magee-Womens Research Institute and Foundation in Pittsburgh, Pennsylvania. The primary objective is to test the feasibility and safety of using adeno-associated virus (AAV) gene therapy to restore fertility in mammalian Sertoli cell dysfunction models. This research aims to...
This $195,625 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund a 2-year study to test whether AAV9-based GALT gene therapy can prevent long-term complications in a rat model of classic galactosemia. The goal is to evaluate the long-term biochemical and phenotypic efficacy of a single dose of scAAV9-hGALT administered intravenously to neonatal...
This federal Project Grant award, funded by the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $249,000 over 3 years (9/1/2024 - 8/31/2027) to the University of Kansas Center for Research Inc. to conduct research on identifying new therapeutics and molecular mechanisms for Congenital Disorders of Glycosylation (CDGs). The key objectives of this research project are to: 1) Determine the...
This $367,059 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to develop a better understanding of the genomic, epigenomic, and transcriptomic outcomes of gene therapy. The research aims to explore the long-term effects of vector integration, the impact of cell/tissue type and promoters on vector behavior, and the host response to different gene therapy delivery...
This Project Grant award, totaling $498,000.00, was provided by the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865). The funding supports the development of the first murine animal model and adeno-associated virus (AAV)-based gene therapy for mitochondrial diseases caused by mutations in the MTATP6 gene. The key objectives are to 1) develop a novel mitochondria-targeting base editing technology to...
The National Institute of Child Health and Human Development (NICHD) awarded a $295,923 Project Grant to Biostrategies LC under the Child Health and Human Development Extramural Research program (CFDA 93.865). The purpose of the award is to develop a "delivery-enhanced" gene therapy drug comprising an RTB:GALNS fusion protein for treating the rare metabolic disorder Mucopolysaccharidosis Type IVA (Morquio A Syndrome). The key objectives are to: 1) optimize the RTB:GALNS construct for...
This $380,546 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) supports research to define how post-transcriptional regulation of gene expression shapes the function of spermatogonial stem and progenitor cells in the mouse model. The key objectives are to: 1) Investigate how the RNA-binding protein DAZL enhances retinoic acid-mediated transcriptional and translational changes to induce...
This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) will support research at Duke University to develop strategies for identifying candidate individuals for early genetic therapies. The key products and services to be delivered under this $153,252 award include: Reevaluating and refining guidelines for universal preconception carrier screening to improve uptake of testing and early...
This $1,149,164 Project Grant awarded by the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) will investigate ethical and policy challenges facing the gene therapy ecosystem. The Hastings Center, a leading non-profit bioethics research institute, will: Analyze documents from federal/state policymakers and organizations to characterize gene therapy challenges and associated ethical/policy issues. Conduct surveys with physicians and in-depth interviews with experts...